LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Sepsis, a common complication following burns, trauma, and major surgery, remains the leading cause of death among critically ill patients. Globally, there are about 48.9 million sepsis patients and ...
Representative clinical studies are important as diseases and medicines can affect people differently depending on their age, sex, and race and ethnicity. According to the Food and Drug Administration ...
It is well known within the biopharma industry that clinical studies can produce any number of unexpected and possibly disappointing outcomes, including false negative results, or in statistical ...
This study is led by Professor Xin Sun (Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-based Medicine Center, Cochrane China and IDEAL China Center, West China ...
Clinical studies remain one of the most difficult phases in medical device development. They’re slow, expensive, and sometimes unpredictable — but completely necessary for nearly everything that ...
Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...
Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...
Industry sponsors will be required to submit diversity action plans for certain key clinical studies of drugs and devices, according to draft guidance released recently by the US Food and Drug ...
As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results